ECI 301

Drug Profile

ECI 301

Alternative Names: ECI301

Latest Information Update: 20 May 2016

Price : $50

At a glance

  • Originator Effector Cell Institute
  • Developer Effector Cell Institute; National Institute on Aging
  • Class Antineoplastics; Chemokines; Proteins
  • Mechanism of Action Leukocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cancer; Hepatocellular carcinoma

Most Recent Events

  • 01 Apr 2016 Phase-I development is ongoing
  • 30 Sep 2011 Phase-I clinical trials in Cancer in USA (IV)
  • 07 May 2010 Preclinical development is ongoing in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top